Navigation Links
Raptor Pharmaceutical Corporation Announces Presentation of Data for NGX426, a Novel, Non-Opioid Oral Analgesic, at Neuropathic Pain Conference
Date:11/4/2009

able to retain or attract key employees whose knowledge is essential to the development of its products; that unforeseen scientific difficulties develop with the Company's process; that Raptor's patents are not sufficient to protect essential aspects of its technology; that competitors may invent better technology; that Raptor's products may not work as well as hoped or worse, that the Company's products may harm recipients; and that Raptor may not be able to raise sufficient funds for development or working capital. As well, Raptor's products may never develop into useful products and even if they do, they may not be approved for sale to the public. Raptor cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in the Company's filings from time to time with the Securities and Exchange Commission (the "SEC"), which Raptor strongly urges you to read and consider, including the joint proxy statement/prospectus on Form S-4 filed with the SEC on August 19, 2009; Raptor's annual report on Form 10-K filed with the SEC on March 27, 2009; Raptor's quarterly report on Form 10-Q filed with the SEC on August 11, 2009; Raptor's wholly-owned subsidiary's, Raptor Pharmaceuticals Corp. ("RPC") Registration Statement on Form S-1, as amended, that was declared effective on August 7, 2008; RPC's annual report on Form 10-K filed with the SEC on October 28, 2009, all of which are available free of charge on the SEC's web site at http://www.sec.gov. Subsequent written and oral forward-looking statements attributable to Raptor or to persons acting on its behalf are expressly qualified in their entirety by the cautionary statements set forth in Raptor's reports filed with the SEC. Raptor expressly disclaims any intent or obligation to update any forward-looking statements.

 
'/>"/>
SOURCE Raptor Pharmaceutical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Merriman Curhan Ford Acted as Financial Advisor to TorreyPines Therapeutics, Inc. in the Completed Merger With Raptor Pharmaceuticals Corp.
2. Raptor Pharmaceutical Expands Board of Directors
3. Raptor Pharmaceuticals Corp. and TorreyPines Complete Merger
4. Raptor Pharmaceuticals Receives Notices of Allowance for Two NeuroTrans(TM) Patent Applications
5. Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
6. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
7. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
8. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
9. Raptor Pharmaceuticals Provides Update on Targeting Platforms
10. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
11. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... 7, 2015   Bionik Laboratories Corp. ... with a core focus in robotic exoskeleton technology ... "Company"), announced today that it has completed an ... consisting of its common stock and warrants for ... a private placement transaction.  This equity financing is ...
(Date:7/7/2015)... Oasmia Pharmaceutical AB, a ... human and veterinary oncology, today announced that it ... the United States , designed to generate ... therapeutic.      (Logo: http://photos.prnewswire.com/prnh/20150420/740096) , ... Paccal Vet-CA1 was previously distributed by ...
(Date:7/7/2015)...  Monopar Therapeutics LLC, an emerging biopharmaceutical company focusing ... and CEO, Chandler D. Robinson MD, MBA, ... Award. The British Council selected one recipient from each ... , and the United States ... who have leveraged their U.K. education in their subsequent ...
Breaking Medicine Technology:Bionik Laboratories Completes US$13.1 Million Private Placement 2Bionik Laboratories Completes US$13.1 Million Private Placement 3Oasmia Pharmaceutical Launches US Brand and Sales Platform 2Monopar Therapeutics Announces Founder And CEO Chandler Robinson Awarded The British Council's Education U.K. Alumni Award 2Monopar Therapeutics Announces Founder And CEO Chandler Robinson Awarded The British Council's Education U.K. Alumni Award 3
... pharmaceutical and medical device companies evolve, market research ... refining current ones to support intelligent planning and ... beginning to explore different types of technological advances ... external data collection and internal asset creation. ...
... 2012   CareFusion Corp. (NYSE: CFN ... that its board of directors authorized the repurchase of ... (Logo:  http://photos.prnewswire.com/prnh/20100706/CAREFUSIONLOGO ) "This ... potential and our commitment to increasing shareholder value," said ...
Cached Medicine Technology:Pharmaceutical Industry Leveraging New Tools to Overcome Challenges in Market Research 2CareFusion Announces $500 Million Share Repurchase Program 2CareFusion Announces $500 Million Share Repurchase Program 3
(Date:7/7/2015)... ... July 07, 2015 , ... ... to interact with fans and provide frozen yogurt offerings at Live Nation's amphitheaters ... truck will be on site at concerts throughout the summer and brand ambassadors ...
(Date:7/7/2015)... ... July 07, 2015 , ... Leading ... expert Jay Warden as Senior Vice President, heading the firm’s Healthcare Advisory Services ... the best solutions to healthcare providers’ needs in ways that strengthen their position ...
(Date:7/7/2015)... ... 07, 2015 , ... Ticket Down is a reputable source of authentic tickets for the 2015 ... vs. Honduras at the Toyota Stadium. , The 2015 CONCACAF Gold Cup is ... The tournament, being held on American soil, will kick off in Frisco, CA from the ...
(Date:7/7/2015)... ... 2015 , ... Greatist today announced the acquisition of Blood, ... the most fun activities to do with friends. , The acquisition of BSC strengthens ... opportunity for events, e-commerce, and brand partnerships. , “I’ve been a huge fan of ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... global provider of advanced delivery technologies and development solutions for drugs, biologics ... licensing agreement with Excelimmune, Inc. to access its antibody combination therapy (ACT) ...
Breaking Medicine News(10 mins):Health News:sweetFrog Mobile Trucks to Offer Froyo at Live Nation Venues 2Health News:Hammes Company Hires Jay Warden to Lead Healthcare Advisory Services 2Health News:Hammes Company Hires Jay Warden to Lead Healthcare Advisory Services 3Health News:Panama vs Haiti & USA vs Honduras CONCACAF Group A Tickets at Toyota Stadium: Ticket Down Slashes Ticket Prices for Haiti vs Panama & USA vs Honduras in Frisco/Dallas 2Health News:Panama vs Haiti & USA vs Honduras CONCACAF Group A Tickets at Toyota Stadium: Ticket Down Slashes Ticket Prices for Haiti vs Panama & USA vs Honduras in Frisco/Dallas 3Health News:Greatist Acquires Active Lifestyle Brand Blood, Sweat & Cheers 2Health News:Catalent Biologics Adds New Technology Platform to Enable Antibody Combination Therapies 2
... 13, 2007 Schizophrenia is one of the most debilitating ... the most difficult to treat. Although numerous antipsychotic treatments ... patients experience only a partial relief of their symptoms and ... new study scheduled for publication in the December 15th issue ...
... to achieving financial ... success, ... that it was launching "The Power of Deliberate Creation," a,two-disc set and ... in a 7 step process. According to,inspirational author and financial success "guru" ...
... 13 Naviscan PET Systems(R), a,privately held company specializing ... Antonio Breast Cancer Symposium -- new clinical,data from a ... management., PEM Flex(TM) Solo II is a commercially ... small body parts such as the,breast and hand. Solo ...
... Phase II Study of Ofatumumab in Relapsed ... Diffuse Large B-Cell Lymphoma, COPENHAGEN, ... centers have been initiated and are,ready to enroll patients in a ... Large B-Cell Lymphoma (DLBCL) in,patients ineligible for or relapsed following a ...
... Dec. 13 ,GlaxoSmithKline (GSK) plc today presented an overview of its neuroscience,portfolio and ... York., ... Highlights, -- Innovative neuroscience pipeline ... schizophrenia, and multiple sclerosis (MS): ...
... U.S. Preventive Medicine(R),a company that is building ... the,United States and internationally ( http://www.USPreventiveMedicine.com ),announced ... intent with iHealth UK Ltd. to,jointly develop ... Kingdom.,iHealth brings together leading clinicians, advanced modalities, ...
Cached Medicine News:Health News:Effective new treatment for schizophrenia 2Health News:John Alexandrov Reveals 'the Secret' to Financial Success Via Launch of 'The Power of Deliberate Creation' Audio CDs 2Health News:John Alexandrov Reveals 'the Secret' to Financial Success Via Launch of 'The Power of Deliberate Creation' Audio CDs 3Health News:Naviscan's PEM Flex(TM) Scanner Shows Promising New Data in Breast Cancer Management 2Health News:Genmab Initiates Ofatumumab Phase II Study in Diffuse Large B-Cell Lymphoma 2Health News:Genmab Initiates Ofatumumab Phase II Study in Diffuse Large B-Cell Lymphoma 3Health News:GlaxoSmithKline Presents Innovative Neuroscience Pipeline 2Health News:GlaxoSmithKline Presents Innovative Neuroscience Pipeline 3Health News:GlaxoSmithKline Presents Innovative Neuroscience Pipeline 4Health News:GlaxoSmithKline Presents Innovative Neuroscience Pipeline 5Health News:GlaxoSmithKline Presents Innovative Neuroscience Pipeline 6Health News:GlaxoSmithKline Presents Innovative Neuroscience Pipeline 7Health News:GlaxoSmithKline Presents Innovative Neuroscience Pipeline 8Health News:U.S. Preventive Medicine to Expand into England with iHealth UK Ltd. 2Health News:U.S. Preventive Medicine to Expand into England with iHealth UK Ltd. 3
The 920M PLUS handheld pulseoximeter provides on-the-spot bloodoximetry and heart rate readings....
Rad-5 signal extraction pulse oximeter™...
... 3100 is a small, lightweight ... worn comfortably on the patients ... activities and for overnight studies, ... WristOx is intended to give ...
The pocket-size Invacare Digit finger pulse oximeter is a convenient and economical solution to fast, reliable SpO2, pulse rate and pulse strength measurements. Its compact size is ideal for home use...
Medicine Products: